The doses below reflect FDA-approved labeling for tirzepatide and clinical trial data for mazdutide
Michael Chen, a reproductive endocrinologist, notes, While these changes can be concerning for patients, its important to remember that theyre often temporary and related to the body adjusting to rapid weight loss rather than a direct effect of the medication.[2] Weight Loss vs
Watch the interview at AJMC - The American Journal of Managed Care #Obesity #MetabolicHealth #MASLD #GLP1 #ADA2026 #Survodutide #LiverHealth To view or add a comment, sign in Very interesting explainer from Elizabeth Cooney on pulmonary hypertension, and why the new class of obesity drugs might help: To view or add a comment, sign in Obesity is not just a weight issue
Paz Departamento de Ciencia y Produccin Agropecuaria, Escuela Agrcola Panamericana
The American Journal of Gastroenterology, 100 (12), 26332636